Therapeutic | Galvokimig2 |
Target | IL13 |
Heavy Chain | EVQLVQSGAEVKKPGSSVKVSCKASGYSFTSYYIHWVRQAPGQCLEWMGRIGPGSGDINYNEKFKGRATFTVDKSTSTAYMELSSLRSEDTAVYYCARFHYDGADWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCKASQNINENLDWYQQKPGKAPKLLIYYTDILQTGIPSRFSGSGSGTDYTLTISSLQPEDFATYYCYQYYSGYTFGCGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv) |
Isotype | na |
Highest Clinical Trial (August '23) | TBC |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | |
INN Year Proposed | 2023 |
INN Year Recommended | None |
Companies Involved | TBC |
Conditions Approved | TBC |
Conditions Active | TBC |
Conditions Discontinued | TBC |
Notes | Final scFv segment. Fv3 identical to Donzakimig Fv3. |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]